Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

Iclusig remains highly effective at lower doses with very minimal side effects according to a CML patient.

"The drug still remains highly effective with few side effects at low dosages."
http://seekingalpha.com/user/6716051/comments/3

Patient loganj2 comented:

The low dose therapy is highly effective with very minimal side effects. I have been on this treatment for two years and 4 months. Originally started at 45mg and after 1 month had adverse side effects (pancreatitus), the dosage was cut to 15 mg. Within 1 month the leukemia was undetectable and has stayed that way. This is a far better response than I had on any of the other TKI's either in development or FDA approved. Not only did every other TKI lose effacacy, the side effects on some of them were far worse than Iclusig. Admittedly this is anechdotal and specific only to my case but it does show that there is much more to be learned about this drug and the potential for market success. The other more disconcerting issue to me personally is that if this drug is no longer available, I have no other treatment options. I do not have the T351I mutation so that has no bearing on the effacy of the drug. I realize that this is all looked at from a business perspective - at least I, and many others like me, demonstrate that there is a potential market for this drug.
http://seekingalpha.com/user/6716051/comments/2